Artivion VP regulatory Andrew Green sells $228,540 in stock

Andrew M. Green, Vice President of Regulatory at Artivion, Inc. (NYSE:AORT), has sold 7,618 shares of the company's common stock, according to a recent SEC filing. The shares were sold at a price of $30 each, amounting to a total transaction value of $228,540. The transaction comes as Artivion's stock trades near its 52-week high, having delivered an impressive 66% return year-to-date. Following this sale, Green retains ownership of 33,503 shares in the company. This transaction was carried out under a 10b5-1 trading plan that Green adopted on August 13, 2024. With analysts setting price targets between $32 and $35, and the stock currently appearing overvalued according to InvestingPro Fair Value metrics, investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through the InvestingPro platform.

In other recent news, medical device sector leader, Artivion, has reported strong financial performance in its Q3 2024 earnings call. The company revealed a 10% year-over-year increase in constant currency, with revenues reaching $95.8 million and adjusted EBITDA experiencing a significant 28% rise to $17.7 million. This growth was largely driven by robust sales of key products and market expansion in Latin America and Asia Pacific.

Artivion's product growth was notable with On-X, BioGlue, and stent grafts up by 15%, 14%, and 13% respectively. Despite a modest 2% growth in tissue processing, the company anticipates full-year revenue growth of 10% to 12%. The company's outlook also projects a net leverage decrease to 3.5x by year-end, with R&D expenses expected to remain consistent relative to sales.

Analysts have noted the company's U.S. market share increase by 55% and the potential $150 million market opportunity with the FDA approval of the AMDS device. The company is also focusing on the significant opportunity of BioGlue in China, expecting meaningful progress in H2 2025. These recent developments underline Artivion's continued growth and market expansion strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.